Proarrhythmia

被引:48
作者
Friedman, PL [1 ]
Stevenson, WG [1 ]
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med,Cardiovasc Div,Cardiac Arrhythmia Serv, Clin Electrophysiol Lab, Boston, MA 02115 USA
关键词
D O I
10.1016/S0002-9149(98)00586-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Proarrhythmia is defined as the provocation of a new arrhythmia or the aggravation of a pre-existing one during therapy with a drug at doses or plasma concentrations below those considered to be toxic, Suggested criteria far proarrhythmia include (1) the new appearance of a sustained ventricular tachyarrhythmia; (2) change from a nonsustained to a sustained tachyarrhythmia; (3) acceleration of tachycardia rate; or (4) the new appearance of a clinically significant bradyarrhythmia or conduction defect, Proarrhythmia can be the direct result of a drug's electrophysiologic effects on conduction velocity, refractoriness, and automaticity, However, it may also be the result of metabolic abnormalities, changes in autonomic state, or drug/drug interactions that amplify or alter the drug's electrophysiologic effects. Some forms of ventricular proarrhythmia, such as torsade de pointes, are difficult to forecast and occur in patients with structurally normal hearts as well as in those with serious heart disease. Of her forms of ventricular proarrhythmia, such as monomorphic ventricular tachycardia, occur predominantly in patients with structural heart disease or pre-existing ventricular arrhythmia. Atrial flutter with 1 : 1 conduction and bradyarrhythmias can be manifestations of proarrhythmia, particularly during drug therapy for atrial fibrillation. In patients with pacemakers or implantable cardiac defibrillators, antiarrhythmic drugs can change pacing thresholds and can alter the ability of a device to recognize or terminate a sustained ventricular tachyarrhythmia, (C)1998 by Excerpta Medica, Inc.
引用
收藏
页码:50N / 56N
页数:7
相关论文
共 45 条
[21]  
Kerr WJ, 1922, HEART-J STUD CIRC, V9, P269
[22]   Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital [J].
Maisel, WH ;
Kuntz, KM ;
Reimold, SC ;
Lee, TH ;
Antman, EM ;
Friedman, PL ;
Stevenson, WG .
ANNALS OF INTERNAL MEDICINE, 1997, 127 (04) :281-+
[23]   FEMALE GENDER AS A RISK FACTOR FOR TORSADES-DE-POINTES ASSOCIATED WITH CARDIOVASCULAR DRUGS [J].
MAKKAR, RR ;
FROMM, BS ;
STEINMAN, RT ;
MEISSNER, MD ;
LEHMANN, MH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (21) :2590-2597
[24]   AMIODARONE IN PATIENTS WITH PREVIOUS DRUG-MEDIATED TORSADE DEPOINTES - LONG-TERM SAFETY AND EFFICACY [J].
MATTIONI, TA ;
ZHEUTLIN, TA ;
SARMIENTO, JJ ;
PARKER, M ;
LESCH, M ;
KEHOE, RF .
ANNALS OF INTERNAL MEDICINE, 1989, 111 (07) :574-580
[25]   CLINICAL CHARACTERISTICS OF PATIENTS WITH VENTRICULAR-FIBRILLATION DURING ANTIARRHYTHMIC DRUG-THERAPY [J].
MINARDO, JD ;
HEGER, JJ ;
MILES, WM ;
ZIPES, DP ;
PRYSTOWSKY, EN .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (05) :257-262
[26]   RISK-FACTORS FOR THE DEVELOPMENT OF PROARRHYTHMIC EVENTS [J].
MORGANROTH, J .
AMERICAN JOURNAL OF CARDIOLOGY, 1987, 59 (11) :E32-E37
[27]   FLECAINIDE - ITS PROARRHYTHMIC EFFECT AND EXPECTED CHANGES ON THE SURFACE ELECTROCARDIOGRAM [J].
MORGANROTH, J ;
HOROWITZ, LN .
AMERICAN JOURNAL OF CARDIOLOGY, 1984, 53 (05) :B89-B94
[28]   ATRIAL-FLUTTER IN PATIENTS TREATED FOR ATRIAL-FIBRILLATION WITH PROPAFENONE [J].
MURDOCK, CJ ;
KYLES, AE ;
YEUNGLAIWAH, JA ;
QI, AH ;
VORDERBRUGGE, S ;
KERR, CR .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (07) :755-757
[29]   REVERSAL OF PROARRHYTHMIC EFFECTS OF FLECAINIDE ACETATE AND ENCAINIDE HYDROCHLORIDE BY PROPRANOLOL [J].
MYERBURG, RJ ;
KESSLER, KM ;
COX, MM ;
HUIKURI, H ;
TERRACALL, E ;
INTERIAN, A ;
FERNANDEZ, P ;
CASTELLANOS, A .
CIRCULATION, 1989, 80 (06) :1571-1579
[30]   Early afterdepolarizations produced by d,l-sotalol and clofilium [J].
Patterson, E ;
Scherlag, BJ ;
Lazzara, R .
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 1997, 8 (06) :667-678